Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 86,224,464
  • Shares Outstanding, K 2,459,340
  • Annual Sales, $ 37,798 M
  • Annual Income, $ 1,236 M
  • 36-Month Beta 1.00
  • Price/Sales 2.26
  • Price/Cash Flow 8.71
  • Price/Book 13.54

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.72 +0.98%
on 11/15/17
40.85 -14.17%
on 10/23/17
-5.78 (-14.15%)
since 10/20/17
3-Month
34.72 +0.98%
on 11/15/17
41.24 -14.98%
on 10/19/17
-4.07 (-10.40%)
since 08/22/17
52-Week
34.72 +0.98%
on 11/15/17
44.53 -21.27%
on 05/31/17
-2.98 (-7.83%)
since 11/22/16

Most Recent Stories

More News
GSK Submits Landmark IMPACT Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA)...

INVA : 13.42 (+0.07%)
GSK : 35.06 (+0.72%)
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen

J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.

JNJ : 137.29 (-0.76%)
GILD : 72.82 (+0.43%)
PFE : 35.43 (-0.31%)
GSK : 35.06 (+0.72%)
Novartis (NVS) Receives EC Nod for Tasigna Label Expansion

Novartis (NVS) oncology portfolio gets a boost with EC's approval for the label expansion of Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic...

SCMP : 10.40 (+0.48%)
LLY : 83.68 (+0.20%)
NVS : 84.48 (+0.24%)
GSK : 35.06 (+0.72%)
Corporate News Blog - GlaxoSmithKline and Innoviva's Trelegy Ellipta Gets Marketing Authorization for the Treatment of COPD in Europe

LONDON, UK / ACCESSWIRE / November 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for GlaxoSmithKline PLC (NYSE: GSK) ("GSK"), following which we...

INVA : 13.42 (+0.07%)
GSK : 35.06 (+0.72%)
Theravance Shares Rise on Approval of Glaxo's COPD Therapy

Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.

TBPH : 28.24 (-1.05%)
MYL : 37.28 (+0.13%)
INVA : 13.42 (+0.07%)
GSK : 35.06 (+0.72%)
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with...

TBPH : 28.24 (-1.05%)
INVA : 13.42 (+0.07%)
JNJ : 137.29 (-0.76%)
GSK : 35.06 (+0.72%)
Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone ...

INVA : 13.42 (+0.07%)
GSK : 35.06 (+0.72%)
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.

AZN : 33.83 (+0.30%)
TEVA : 13.48 (+1.13%)
AMGN : 169.96 (+0.07%)
GSK : 35.06 (+0.72%)
Glaxo's Subcutaneous Formulation of Benlysta Approved in EU

GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.

CORT : 17.75 (+0.97%)
SCMP : 10.40 (+0.48%)
ACHN : 3.36 (-2.04%)
GSK : 35.06 (+0.72%)
Featured Company News - Adaptimmune Outlines Study Designs for Two T-Cell Clinical Trials - MAGE-A4 and NY-ESO SPEAR

Research Desk Line-up: Jazz Pharma Post Earnings Coverage

JAZZ : 138.04 (+0.62%)
ADAP : 8.11 (+2.85%)
GSK : 35.06 (+0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

2nd Resistance Point 35.33
1st Resistance Point 35.20
Last Price 35.06
1st Support Level 34.95
2nd Support Level 34.83

See More

52-Week High 44.53
Fibonacci 61.8% 40.78
Fibonacci 50% 39.63
Fibonacci 38.2% 38.47
Last Price 35.06
52-Week Low 34.72

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart